Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Most Read

  1. Vertex-Semma $950m acquisition: bringing diabetes into the pipeline
  2. Takeda-Shire deal: the strategy behind Japan’s largest foreign acquisition
  3. Boehringer acquires AMAL Therapeutics for $366m
  4. Pfizer acquires rare disease biotech Therachon for $340m
  5. GSK and University of California team up on CRISPR research

Company A-Z

Latest Content

IFM Due signs immunotherapy deal with Novartis

IFM Due, a subsidiary of IFM Therapeutics, has entered a collaboration and exclusive option agreement with Novartis for the development of immunotherapies to address severe inflammatory and autoimmune disorders.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:


Go Top